Meeting
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
Authors
Hui Liu
The First Affiliated Hospital, Zhejiang University, Hangzhou, China
Hui Liu , Wen Lei , Chaoting Zhang , Chunmei Yang , Juying Wei , Qunyi Guo , Xiaojun Guo , Zhilu Chen , Ying Lu , Zheming Lu , Wenbin Qian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03258047
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7557)
DOI
10.1200/JCO.2019.37.15_suppl.7557
Abstract #
7557
Poster Bd #
311
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Loretta J. Nastoupil
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2021 ASCO Annual Meeting
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
First Author: Zhongwei Zhao
Poster
2017 ASCO Annual Meeting
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
First Author: Bo Zhai